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Antimicrobial resistance is a global threat to human and ani-
mal health and has major economic impacts.1,2 Antimicrobials 
are used in animal production to prevent or treat infectious 
diseases and to promote growth.3 The total quantity of anti-
microbials used in animals is projected to increase by 67%, 
from 63 151 to 105 596 tonnes, between 2010 and 2030 due to 
increasing demand for animal food products globally and to 
more intensive animal farming practices in several middle-in-
come countries.4 The extent to which the use of antimicrobials 
in animals contributes to the risk of developing antimicrobial 
resistance in humans at a global scale is unknown. A growing 
number of studies, however, provide support for causal rela-
tionships between antimicrobial use and resistance in animals 
and in humans at the local and regional scale.5 Consequently, 
surveillance systems that integrate information about resis-
tance of microorganisms circulating in humans, animals and 
the environment are needed to enhance our understanding 
of the complex epidemiology of antimicrobial resistance and 
to inform targeted action. This integrated approach is known 
as One Health surveillance.6 One Health surveillance for 
antimicrobial resistance has been promoted by international 
organizations for more than a decade and constitutes a central 
recommendation of the World Health Organization (WHO) 
Global action plan on antimicrobial resistance.7
To assist countries in the development of surveillance 
systems, the WHO Advisory Group on Integrated Surveillance 
of Antimicrobial Resistance released its new guidelines on the 
application of a One Health approach to surveillance of anti-
microbial resistance in foodborne bacteria in 2017.8 The report 
recommends detailed minimal requirements that each country 
should implement for an effective One Health approach.
In this article, we discuss three important issues that must be 
addressed to improve our understanding of the global effective-
ness of One Health surveillance for antimicrobial resistance and 
to support countries in the development of such systems. First, 
we emphasize the need to better understand the mechanisms 
through which a One Health integrated approach enhances the 
effectiveness and value of surveillance systems. Second, we argue 
that more emphasis should be placed on transdisciplinary teams 
and networks brought together by the One Health approach. 
Third, we highlight that research is still needed to develop and 
evaluate conceptual and analytical tools for measuring the degree 
of integration and estimating the effect of this integration on 
health outcomes. Each topic is discussed in detail in the following 
sections. Our views are informed by ongoing work by ourselves 
and others that aims to evaluate the added value of One Health 
for the surveillance of antimicrobial resistance at the human–
animal interface in Canada, Europe and globally.6,9–11 We use 
the Canadian Integrated Program on Antimicrobial Resistance 
Surveillance to illustrate many of our points.
The value of integration
The Advisory Group on Integrated Surveillance of Antimicro-
bial Resistance guidelines describe in detail the diverse types 
of data that should be collected and analysed in a system for 
surveillance of antimicrobial resistance in foodborne bacteria.8 
The guidelines recommend the collection of standardized and 
comparable data on antimicrobial resistance in bacteria from 
retail food products and humans and, if possible, data on an-
timicrobial use in humans and food-producing animals. The 
guidelines provide suggestions about which animal species 
and types of production should be targeted in relation to the 
food consumption patterns in the human population and the 
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expected prevalence of antimicrobial 
resistance in animal populations. The 
surveillance system “may be modified 
from year to year to capture multiple 
commodities”. The guidelines also recom-
mend which bacteria and antimicrobials 
to consider and stress the need to include 
samples from the environment. These 
recommendations are made with the 
implicit assumption that more data are 
inherently beneficial, without providing 
strong evidence about the added value 
of this approach or any recommenda-
tions about how One Health surveillance 
systems should be evaluated. Readers 
of the guidelines are encouraged to use 
existing integrated surveillance systems, 
such as those of Canada, Denmark, the 
Netherlands, Norway, the Republic of 
Korea, Sweden and the United States of 
America, as models for the development 
of new programmes in other countries.8
However, even though these model 
surveillance systems are all considered to 
be highly integrated, their levels of, and 
approaches to, One Health integration 
differ in many ways. For example, the 
Canadian Integrated Program for Anti-
microbial Resistance Surveillance is oper-
ated entirely within a federal public health 
organization: the Public Health Agency of 
Canada. The programme collects annual 
resistance data on three microorganisms 
that are pathogens of humans (Salmonella 
spp., Campylobacter spp.) or are sentinel 
bacteria (Escherichia coli) from three main 
animal groups (poultry, pigs and cattle). 
Data are collected at different points along 
the food-chain, including the farm, the 
abattoir and retail food stores.12 In contrast, 
the Swedish surveillance system divides 
its operations between the animal and hu-
man health sectors. The Swedish National 
Veterinary Institute operates the Swedish 
Veterinary Antibiotic Resistance Moni-
toring programme and the Public Health 
Agency of Sweden manages the Swedish 
Antibiotic Utilization and Resistance in 
Human Medicine programme; the results 
are published in a joint report.13 The Swed-
ish system integrates resistance data from 
several animal pathogens, including from 
companion animals, and varies the targeted 
animal species over time. The surveillance 
systems in Denmark, the Netherlands, 
Norway, the Republic of Korea and the 
United States all have different structures 
and processes, different target microor-
ganisms and antimicrobials, and different 
points of collaboration across sectors.14–17 
With such diversity, it may be difficult 
for countries with little or no experience 
with antimicrobial resistance surveillance 
to identify priorities and to construct an 
informed development plan to establish 
an integrated One Health surveillance sys-
tem. Moreover, despite years of experience 
with One Health surveillance in several 
countries, evidence is still lacking that the 
performance and cost–effectiveness of 
highly integrated surveillance systems are 
better than less integrated systems. We 
therefore conclude that there is a need 
to move from generic guidelines for One 
Health integration to empirical evidence 
that can guide the design of surveillance 
systems. To produce such evidence, re-
search is needed to assess the added value 




In the Advisory Group on Integrated 
Surveillance of Antimicrobial Resistance 
report, integrated surveillance of antimi-
crobial resistance in foodborne bacteria 
is defined as “the collection, validation, 
analyses and reporting of relevant mi-
crobiological and epidemiological data 
on antimicrobial resistance in foodborne 
bacteria from humans, animals, and 
food, and on relevant antimicrobial use 
in humans and animals.”8 This defini-
tion tends to reduce the concept of One 
Health to integration of data sets from 
different sources: humans, animals and 
food. Apart from recommendations on 
the types of data that should be collected, 
the report presents some examples of in-
tegrated analysis and reporting formats. 
However, there is no clear guidance on 
other essential dimensions of One Health 
systems, such as intersectoral collabora-
tion and information sharing.11
Collecting data from humans, ani-
mals and the environment is crucial to 
the concept of One Health and consti-
tutes an important first step towards an 
integrated approach. However, the inter-
disciplinary nature of One Health sur-
veillance generates outcomes that go be-
yond the value of information produced 
from integrated data collection. Also, to 
capture the added value of One Health 
surveillance, we need to revisit how we 
characterize and measure the integration 
of a surveillance system. In Table 1, we 
illustrate how One Health integration 
applies to all activities of a surveillance 
system from data collection to analyses, 
interpretation and dissemination. In each 
activity, integration can be achieved at 
different points and to differing extents 
in terms of the type of data integrated; 
the operations and processes used to 
integrate the data; and the collaboration 
of stakeholders that are implementing or 
benefiting from the activities. The level of 
integration can therefore be conceptual-
ized, measured and increased for each 
surveillance activity.
At the level of data collection, in-
tegration can be increased by sampling 
from different animal species, produc-
tion types, points along the food-chain, 
locations in the environment and species 
of microorganisms; and according to 
risk factors. For example, the Canadian 
Integrated Program on Antimicrobial 
Resistance Surveillance has increased 
its level of integration gradually over 
the years by adding collection points 
along the animal production system. The 
programme started by integrating data 
on antimicrobial resistance from animal 
samples collected at abattoirs with data 
on antimicrobial resistance from sick ani-
mals and humans. Over the next 15 years 
the programme added other type of data, 
including antimicrobial resistance of 
organisms in farm samples and in retail 
meat samples from different provinces, 
and the use of antimicrobials both in 
animal production and human health.
Integration can also be increased by 
harmonizing sample and data analyses 
methods across sectors to enhance the 
comparability of the information pro-
duced; or by centralizing surveillance 
operations related to data collection 
across one or more institutions. At the 
level of data analysis and interpretation, 
integration can be enhanced by mov-
ing from simple comparisons of trends 
between animal and human data sets 
towards multivariable analysis that, for 
example, controls for the effect of differ-
ent risk factors. Moreover, One Health 
integration can be increased by including 
multiple disciplines in the analyst team. 
For example, the Canadian programme 
team is composed of epidemiologists and 
experts in avian, swine and bovine medi-
cine as well as public health. This One 
Health team is key for analysis and inter-
pretation of the surveillance information 
in context, and for the dissemination of 
surveillance information to a broad and 
multidisciplinary network of end-users. 
At the level of information dis-
semination, integration can be increased 
by moving from producing different 
reports for each animal species to in-
tegrating all surveillance information 
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into a joint report, and by increasing the 
multidisciplinary nature of the network 
that is reached by these dissemination 
products.18 The Canadian programme 
team engages with over 600 stakehold-
ers with expertise in animal and public 
health. Those involved include livestock 
and poultry producers; veterinary phy-
sicians; physicians and their licensing 
bodies; local, provincial and federal 
public health and animal health organi-
zations; pharmaceutical organizations; 
drug and food regulators; animal and 
farm advocacy groups; and researchers. 
These stakeholders are invited to discuss 
integrated information on antimicrobial 
resistance at events, such as the annual 
stakeholder’s meeting of the Canadian 
Integrated Program on Antimicrobial 
Resistance Surveillance. The One Health 
network of stakeholders would not be 
able to exchange views and information 
to the same extent without the support 
of the Canadian programme team. Con-
sequently, the surveillance team and its 
network of engaged stakeholders are es-
sential to ensure that the information is 
used for decision-making and for induc-
ing change in the use of antimicrobials in 
animal and human populations. Hence, 
we propose that the team and its network 
can be seen as direct contributors to the 
effectiveness of the One Health surveil-
lance system (Fig. 1).
Integration in data analysis, inter-
pretation and dissemination are im-
portant points in the design of effective 
One Health surveillance systems. We 
have developed a semiquantitative scale, 
based on our experience in the Canadian 
programme, to systematically measure 
the level of integration in antimicrobial 
resistance surveillance systems for food-
borne bacteria. The scale comprises the 
elements that can be integrated in each 
surveillance activity, as we have already 
described, and proposes six levels of 
integration that can help to characterize 
One Health integration (Aenishaenslin 
C et al., Faculty of Veterinary Medicine, 
Université de Montréal, unpublished 
Table 1. Types of integration in a surveillance system for antimicrobial resistance in foodborne bacteria by surveillance activities
Surveillance activity Integration of information Integration in operations and processes Integration of multiple 
institutions, disciplines and 
perspectives
Data collectiona Integration of antimicrobial resistance data 
from: 
• human, animal and environmental 
sources; 
• different animal species; 
• different production type within a 
species (for example organic versus other 
productions) 
• different collection points (farm, abattoir, 
retail meat, water, soil); 
• different microorganism species; 
• different antimicrobials; and 
• active and passive surveillance activities
Standardization across human and 
animal sources of: 
• laboratory methods for samples; and 
• measurement units used to analyse 
and report antimicrobial resistance and 
antimicrobial use
Integration of:  
• data collection in 
one local or national 
organization (versus multiple 
organizations involved in 
animal health and human 
health); and 
• sample analysis in one 
laboratory (versus different 
laboratories for animal 
health, human health or 
others)
Integration of data on antimicrobial 
use and other risk factors (e.g. farm 
management practices)
Data analyses and 
interpretation
Comparisons of data on antimicrobial 
resistance and antimicrobial use from: 
• human, animal and environmental 
sources; 
• different animal species; 
• different animal commodities; 
• different collection points; 
• sick and healthy animals and humans; 
• different geographical locations; and 
• over time
Use of more complex integrated 
statistical analysis (versus simple 
comparisons of trends in data from 
different sources)
Integration of data analysis 
and interpretation: 
• in one institution (versus 
different institutions in 
animal and human health); 
• in one team of analysts 
(versus different individuals 
or teams); and 
• based on the perspectives 
of experts in different 
disciplines and the 
stakeholders involved in data 
interpretation
Analysis of the links between antimicrobial 
use, other risk factors, and antimicrobial 
resistance
Analysis of relationships in antimicrobial 
resistance trends: 
• across data from different sources; and 
• in relation to risk factors
Surveillance information 
dissemination
Integration of information from different 
sources in reporting activities (versus 
separated by sources)
Reporting: 
• using one main harmonized format for 
animal health and human health end-
users (versus multiple formats); 
• at the same time to human and 
animal health stakeholders through at 
least one activity (one report or one 
meeting); and  
• adapted to stakeholders from human 




• coordinated by one 
institution (versus different 
institutions in charge of 
dissemination); and 
• based on the perspectives 
of experts in different 
disciplines and the 
stakeholders involved in 
dissemination
a  Includes sample collection, sample analyses and data centralization.
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data, 2018). We hope that our scale will 
become an essential step in evaluating the 
effectiveness of One Health surveillance 
systems and serve as a guide for countries 
in the process of increasing the level 
of One Health integration within their 
surveillance system.
Evaluating the added value
A greater level of integration in a system 
does not necessarily result in a more 
effective or more cost–effective system. 
Over recent decades, several generic 
frameworks for evaluation of surveillance 
systems in human and animal health have 
been developed by different researchers 
and organizations. The surveillance eval-
uation frameworks in both the public and 
animal health sectors propose groups of 
attributes that can be assessed as indica-
tors of the effectiveness of a surveillance 
system, such as acceptability, data quality, 
data sensitivity, timeliness and cost–ef-
fectiveness.19–21 In line with these frame-
works, researchers have used economic 
analysis to estimate the added value of 
One Health surveillance, although not 
to examine integrated surveillance of 
antimicrobial resistance.22–25
The value of One Health surveil-
lance for antimicrobial resistance can be 
conceptualized and measured across a 
spectrum of different outcomes that can 
be classified as (i) immediate; (ii) inter-
mediate; or (iii) ultimate (Fig. 1). Imme-
diate outcomes include increased under-
standing of the antimicrobial resistance 
epidemiology at the interface across 
human health, animal health and the 
environment; the value of this knowledge 
is in the intellectual or social capital that 
is generated.23 Intermediate outcomes 
include changes in policy or behaviours 
resulting from surveillance information; 
the value in this case is in the size of the 
reduction in antimicrobial resistance that 
results from these changes. Only for the 
ultimate outcomes, improved animal, 
human and environmental health, can 
tangible benefits be measured directly 
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Notes: The logic model illustrates the relationships between immediate, intermediate and ultimate expected outcomes of One Health surveillance. The arrows on 
the left present the growing strength of influence of external factors in achieving more distal outcome.
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in an economic evaluation. Hence, the 
benefits resulting from changes in the 
occurrence of disease in animals and 
humans can be attributed to decisions 
about interventions to mitigate the effect 
of disease (or decisions not to intervene) 
that were implemented because of sur-
veillance outputs.23,24 
Other researchers have concep-
tualized the objectives of One Health 
surveillance according to the epidemio-
logical status of a disease within three 
stages of action to mitigate the disease: 
(i) sustainment; (ii) investigation; and 
(iii) implementation.26 The sustainment 
stage is when the disease incidence is at 
an acceptable level and mitigation efforts 
aim to keep the incidence under a certain 
threshold. In the investigation stage, the 
incidence goes over the acceptable level 
and the mitigation activities aim to col-
lect the indicators (prevalence, morbid-
ity, mortality, risk factors, etc.) that are 
necessary to identify the best points of 
intervention. Finally, in the implementa-
tion stage, the intervention is identified 
and implemented, while surveillance 
aims at evaluating its effectiveness.
Antimicrobial resistance is a com-
plex and, for many countries, a relatively 
new concern. Surveillance information is 
therefore often not yet linked to planned 
interventions and the objectives of anti-
microbial resistance surveillance mainly 
correspond to those in the investigation 
stage. The investigation stage can be 
maintained for years, as the complexity 
of the antimicrobial resistance epidemi-
ology complicates identification of the 
most cost–effective interventions. Also, 
other types of changes that would lead to 
a reduction of antimicrobial resistance in 
animals, humans and their ecosystems, 
such as changes in policies and behav-
iours, are influenced by external factors, 
such as the political context (Fig. 1). Con-
sequently, evaluation of the added value 
of One Health surveillance for antimi-
crobial resistance poses methodological 
challenges. An important step that has 
been neglected so far by researchers and 
public health practitioners is the evalu-
ation of whether and how One Health 
approaches impact policy and behaviour 
changes. Mixed methods and qualitative 
methods, for example in policy analysis, 
should be considered to help under-
stand how information produced by the 
surveillance system is used by different 
stakeholders and decision-makers.
Conclusion
Countries developing One Health sur-
veillance systems need empirical evi-
dence about how to achieve integration 
in a cost–effective manner. Research on 
how the performance of One Health 
surveillance systems for antimicrobial re-
sistance are influenced by different levels 
of integration is important for generat-
ing evidence and for benchmarking and 
recommending best practices.
Evidence about the added value of 
One Health surveillance systems is also 
important for effective implementation 
of the global antimicrobial resistance 
surveillance system.27 The system was 
launched in 2015 by WHO to standard-
ize antimicrobial resistance surveillance 
across countries and help support the 
implementation of the global action 
plan on antimicrobial resistance.28 Up to 
now, the global system has focused on 
developing national surveillance systems 
able to produce information on antimi-
crobial resistance in humans that can be 
compared across countries. The global 
system also aims to support countries 
in moving towards surveillance systems 
capable of integrating data on antimi-
crobial resistance in animals. Countries 
will need evidence-based guidelines to 
structure the development of effective 
and efficient integrated surveillance for 
antimicrobial resistance. In addition, 
harmonized evaluation approaches and 
tools that are adapted to the complexity of 
One Health surveillance systems should 
be developed, integrated into the global 
antimicrobial resistance surveillance 
system and promoted at the international 
and national levels.
Evaluating the added value of One 
Health approaches for antimicrobial 
resistance surveillance is not a simple 
task, but it should not be set aside be-
cause of its complexity. We underline 
the need to better define and evaluate 
the components of One Health integra-
tion in antimicrobial resistance surveil-
lance systems. Collaborations among 
One Health surveillance teams and 
their networks should be more carefully 
integrated in the design and evaluation 
of antimicrobial resistance surveillance 
systems and should be better addressed 
in guidelines provided by international 
organizations. ■
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صخلم
تابوركيلما تاداضم ةحفاكم ةبقارم مظنل ةمزلالا ةلدلأا
 تابوركيلما تاداضم ةحفاكلم One Health  ةبقارلم جيوترلا مت
 دقع  نع  ديزي  ام  ذنم  ةيلود  تماظنمو  يملعلا  عمتجلما  ةطساوب
 ةجاحب  يتلا  اياضقلا  لىع ءوضلا  لاقلما  اذه  في طلسن  .نامزلا  نم
 ةحفاكلم  One Health  ةبقارم  ةيلاعف  مهف  ينسحتل  لوانتلل
 لودلا  معدل  ةمزلالا  ةلدلأا  حضون  ماك  .تابوركيلما  تاداضم
 .ابه  صالخا  ةبقارلما  ماظن  في  لماكتلا  ىوتسم  ةدايزل  ططتخ  يتلا
 اننأ  معزن  اننإف  ،ىرخأ  نادلب  براتجو  ةيدنكلا  ةبرجتلا  لىع  ًءانبو
 ماظنل ةفاضلما ةميقلا سايقو مهفل دهلجا نم ديزلما لذب لىإ ةجاحب
 ديدحتلو  ،تابوركيلما  تاداضم  ةحفاكم  ةبقارلم  One Health
 تزكر ،نلآا ىتحو .ةيلاعفلا ثيح نم لماكتلا تايجيتاترسا رثكأ
 لىع سياسأ لكشب ةبقارملل One Health ماظن ريوطت تاداشرإ
 ،كلذ  عمو .اهنيب  مايف  لماكتلا  ثادحإ  يغبني  يتلا  تانايبلا  عاونأ
 ماهم لىع One Health  موهفم قيبطت  يروضرلا نم نوكي دق
 ةلماكلا ةميقلا كاردلإ كلذو ،تانايبلا لماكت زواجتت يتلا ةبقارلما
 عجم) ةفلتخلما ةبقارلما ةطشنأ برع لماكتلا زيزعت نكمي .جهنلا اذله
 رابتعلاا  في  ذخلأا  عم  ،(اهشرنو  اهيرسفتو  اهليلتحو  تانايبلا
 ةحلصلما  باحصأو  ءابرلخا  رظن  تاهجوو  ةفلتخلما  تاراهلما
 تايللآا  في  قيقحتلل  ثاحبلأا  نم  ديزم  لىإ  ةجاح  كانه  .ينينعلما
 نم ديزي نأ ةبقارملل One Health جهنل الهلاخ نم نكمي يتلا
 لىإ ةياهنلا في يدؤي امم ،تابوركيلما تاداضم ةحفاكم ةبقارم ءادأ
.ةيحصلا جئاتنلا ينستح
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Les données empiriques manquent sur les systèmes de surveillance de la résistance aux antimicrobiens
Cela fait plus de dix ans que la communauté scientifique et les 
organisations internationales préconisent l'application de l'approche 
«Un monde, une santé» à la surveillance de la résistance aux 
antimicrobiens. Cet article souligne les éléments à considérer pour 
mieux comprendre l'efficacité d'une surveillance fondée sur cette 
approche. Nous y évoquons également les données requises pour 
éclairer les pays dans la définition de leurs plans nationaux afin 
d'améliorer le niveau d'intégration de leur système de surveillance. À 
partir de l’expérience du Canada et d'autres pays, nous estimons que 
des efforts doivent encore être faits pour comprendre et mesurer la 
véritable valeur ajoutée de l'approche «Un monde, une santé» dans 
le cadre de la surveillance de la résistance aux antimicrobiens et afin 
d'identifier les stratégies d'intégration les plus efficaces. À ce jour, les 
lignes directrices pour l'établissement d'une surveillance fondée sur 
cette approche se sont principalement axées sur les types de données 
qui devraient être intégrées. Néanmoins, pour exploiter toute la 
valeur de cette approche, il pourrait être utile d'appliquer le concept 
«Un monde, une santé» aux activités de surveillance au-delà de la 
simple intégration des données. Une meilleure intégration peut être 
obtenue au niveau des différentes activités de surveillance (collecte, 
analyse, interprétation et diffusion des données) en tenant compte des 
différentes compétences et des différents points de vue des experts et 
des parties prenantes. De nouvelles recherches sont nécessaires pour 
comprendre les mécanismes par lesquels l'approche «Un monde, une 
santé» appliquée à la surveillance peut améliorer les performances de 
la surveillance de la résistance aux antimicrobiens et, en fin de compte, 
améliorer les résultats de santé.
Резюме
Необходимое подтверждение для систем надзора за резистентностью к антимикробным препаратам
Система надзора за резистентностью к антимикробным 
препаратам One Health находит поддержку научного сообщества 
и международных организаций уже в течение более десяти 
лет. В этой статье освещаются проблемы, которые следует 
решить для улучшения понимания эффективности надзора 
за резистентностью к антимикробным препаратам One 
Health. Авторы также описывают характер подтверждений, 
необходимых для поддержки стран, планирующих повысить 
уровень интеграции своих надзорных систем. На основании 
опыта Канады и других стран оспаривается утверждение о 
том, что нужно больше усилий для понимания и измерения 
ценности системы надзора за резистентностью к антимикробным 
препаратам One Health и для выявления наиболее эффективных 
стратегий интеграции. На сегодня рекомендации по разработке 
системы надзора One Health в основном сосредотачивались 
на типах данных, которые следует интегрировать. Однако, 
чтобы оценить всю ценность подхода, может понадобиться 
применение концепции One Health к надзорным задачам, не 
ограничивающимся интеграцией данных. Интеграция может быть 
усилена между разного рода надзорной деятельностью (сбор 
данных, анализ, интерпретация и распространение) с учетом 
различия в навыках и точках зрения специалистов и партнеров, 
участвующих в работе системы. Требуются дополнительные 
исследования для изучения механизмов, посредством которых 
подход One Health к вопросам надзора может улучшить качество 
работы систем надзора за антимикробной резистентностью 
и, в конце концов, улучшить результаты работы системы 
здравоохранения.
Resumen
Pruebas necesarias para los sistemas de vigilancia de la resistencia a los antimicrobianos
La comunidad científica y las organizaciones internacionales han 
promovido durante más de una década la vigilancia sanitaria de la 
resistencia a los antimicrobianos. En este artículo, destacamos las 
cuestiones que deben abordarse para mejorar la comprensión de la 
eficacia de la vigilancia de la resistencia a los antimicrobianos de One 
Health. También esbozamos las pruebas necesarias para apoyar a los 
países que planean aumentar el nivel de integración de su sistema de 
vigilancia. Basándonos en la experiencia de Canadá y de otros países, 
sostenemos que se necesitan más esfuerzos para comprender y medir 
el valor agregado de One Health para la vigilancia de la resistencia a los 
antimicrobianos y para identificar las estrategias de integración más 
eficaces. Hasta la fecha, las directrices para el desarrollo de vigilancia 
de One Health se han centrado principalmente en los tipos de datos 
que deben integrarse. Sin embargo, puede ser necesario aplicar el 
concepto de One Health a tareas de vigilancia que van más allá de 
la integración de datos para aprovechar todo el valor del enfoque. La 
integración puede mejorarse en las diferentes actividades de vigilancia 
(recopilación, análisis, interpretación y difusión de datos), teniendo en 
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cuenta las diferentes competencias y perspectivas de los expertos y 
las partes interesadas. Se necesita más investigación para estudiar los 
mecanismos mediante los cuales un enfoque de vigilancia de One 
Health puede aumentar el rendimiento de la vigilancia de la resistencia 
a los antimicrobianos y, en última instancia, mejorar los resultados 
sanitarios.
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